Combination Of Androgen Receptor Inhibitor And Cisplatin, An Effective Treatment Strategy For Urothelial Carcinoma Of The Bladder
Urologic Oncology: Seminars and Original Investigations(2019)
Abstract
•Bladder cancer (BCa) is about 4 times more common in men than in women, prognosis of patients with advanced BCa remains poor.•Androgen receptor (AR) expression in BCa patients correlate with tumor stage.•Enzalutamide inhibits AR nuclear translocation in BCa, induces apoptosis.•Enzalutamide and Cisplatin combination inhibits cell growth and EMT in AR+ muscle invasive bladder cancer cells.
MoreTranslated text
Key words
Urothelial carcinoma,Androgen receptor,Combination therapy,Muscle invasive bladder cancer
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined